Aurinia Q1 net product revenue $48.1M (+40% YoY); expects Q2 cash flow positive

Aurinia Pharmaceuticals Inc.

2024-Q1 EPS reported -$0.07 revenue$50,303,000

Total net revenue $50.3M (+46% YoY); net loss narrowed to $10.7M ($0.07/sh) from $26.2M.
Restructuring completed with $50-55M annual cost savings; headcount reduced ~25%.
Company expects to be cash flow positive (ex buybacks) in Q2 2024, ahead of prior guidance.
Reaffirms FY2024 net product revenue guidance of $200-220M.
FDA approved label update for LUPKYNIS removing one-year efficacy limitation; quarterly kidney assessment after year one.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aurinia Pharmaceuticals Inc. reported the quarter ended March 31, 2024 results: revenue $50.3 million. Guidance reaffirmed.

Period: the quarter ended March 31, 2024
Revenue: $50.3 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- AURINIA PHARMACEUTICALS REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATIONAL RESULTS • Achieved $50.3 million in total net revenue and $48.1 million in net product revenue for the first quarter of 2024, representing year over year growth of approximately 46% and 40% respectively, and

View on SEC.gov

341 earnings releases filed in the last 30 days. Browse all earnings releases →

Aurinia Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001600620-24-000049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.